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ABSTRACT
Aims: Allergic rhinitis is caused by sensitivity to environmental allergens that can significantly impact
quality-of-life. The objective of this analysis was to estimate health state utilities and quality-adjusted
life days (QALDs) for a tree allergy immunotherapy trial, TT-04 (EudraCT No.2015-004821-15). Health-
state utilities are a measure of patient preference for health states and are necessary to derive QALDs
for cost-utility analysis. Preference-based utilities were not collected in the TT-04 trial, so a mapping
algorithm was developed based on a similar grass allergy immunotherapy trial, GT-08 (EudraCT No.
2004-000083-27), to estimate utilities.
Methods: A two-part model was developed to predict utilities for the GT-08 trial and applied to the
TT-04 trial to estimate the difference in mean utility and QALDs between SQ tree sublingual immuno-
therapy (SLIT)-tablet and placebo.
Results: Mean utility difference between SQ tree SLIT-tablet and placebo was 0.030 [95%
CI¼ 0.015–0.046] during the birch pollen season (BPS), 0.019 [95% CI¼ 0.007–0.030] during the tree
pollen season (TPS) and 0.018 [95% CI¼ 0.007–0.030] during the full trial. The treatment showed a
QALD benefit of 1.26 [95% CI¼ 0.619–1.917] during the BPS, 1.90 [95% CI¼ 0.692–3.047] during the
TPS, and 2.47 [95% CI¼ 0.930–4.101] during the full trial.
Limitations: The generalizability of this algorithm is limited to allergy trials containing the same cova-
riates as those present in the model. The analysis also assumes that grass and tree pollen allergy have
the same relationship with EQ5D utilities, which is supported by the fact that both grass and tree pol-
len induce similar symptoms.
Conclusions: Application of the mapping function enabled the calculation of QALDs associated with
the treatment, with the caveat that data were extrapolated from grass seasonal allergy to tree sea-
sonal allergy. The results showed a significant QALD benefit of the treatment over placebo in treat-
ment of tree pollen-induced rhinoconjunctivitis.
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Introduction
Allergic rhinitis is a common inflammatory disorder of the
nasal mucosa affecting more than 20% of the European
population. Allergic rhinitis is caused by sensitivity to envir-
onmental allergens such as tree or grass pollen1–5.
Symptoms of allergic rhinitis include a runny, itchy, or
blocked nose and itchy, gritty, or watery eyes. An estimated
10–40% of patients also suffer from concomitant allergic
asthma2,3,5,6. In addition to physical symptoms, patients
often experience reduced sleep quality, emotional problems
such as depression, and social difficulties3,5,6. Patients often
require additional general practice services and medication,
which can be a financial burden to patients, healthcare pro-
viders, and society3,6–8.
Treatments for allergic rhinitis include the use of symp-
tom-relieving medications such as oral antihistamines, intra-
nasal corticosteroids, and allergen avoidance, all of which
may provide temporary relief from symptoms1,5,9. Allergy
immunotherapy (AIT) is a treatment for patients with
evidence of Immunoglobulin E (IgE) sensitization whose
moderate-to-severe allergic rhinitis is uncontrolled by symp-
tom-relieving medications10,11. AIT may be administered sub-
cutaneously or sublingually, and contains allergen extracts
from the target allergen5,9,12. In addition to providing relief
from daily symptoms, AIT induces a long-term immune toler-
ance that improves quality-of-life for years past treatment
discontinuation10,13–15.
The effect of allergic rhinitis on quality-of-life may be
assessed by preference-based measures (PBMs) or disease-
specific measures. Generic PBMs assess general quality-of-life
with standardized dimensions broad enough to capture qual-
ity-of-life differences in most disease areas. PBM responses
may be used to generate health-state utilities, which are rela-
tive preference weights for different health states measured
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on a cardinal scale and may be used to calculate quality-
adjusted life years (QALYs), a common outcome in
cost-effectiveness studies and a requirement for cost-utility
analysis. However, the domains of generic questionnaires
may be too broad to be sensitive to condition-specific
symptoms such as ocular or nasal symptoms16–18. Disease-
specific measures of quality-of-life such as the
Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) have
the advantage of greater sensitivity to condition-specific
symptoms, but may not be used to calculate QALYs16–20.
When PBMs are not used in a clinical trial it is possible to
“map” disease-specific scores to preference-based utilities
that may be used to calculate QALYs in cost-effectiveness
studies. A common mapping strategy takes advantage of an
“estimation” dataset, which is a dataset with recorded PBM
data that is similar to the dataset of interest that does not
contain PBM data. Regression modeling is applied to the
estimation dataset to develop a mapping function that quan-
tifies the statistical relationship between the PBM and the
other outcomes measured in the study. The two datasets
must be similar because the mapping function assumes that
the statistical relationship between the estimated utilities
and the covariates are the same in both the estimation data-
set and the study dataset. The regression developed from
the estimation dataset is applied to the study dataset in
order to estimate preference-based health-state utilities19–22.
This analysis developed an algorithm to map from the dis-
ease-specific measure RQLQ to the generic PBM European
Quality-of-Life in 5-Dimensions (EQ5D). The algorithm was
developed from grass allergy immunotherapy trial data (GT-
08), in which both RQLQ and EQ5D data were collected. The
algorithm was applied to a similar tree allergy immunother-
apy trial (TT-04) that did not collect EQ5D data to estimate
health-state utilities and QALYs.
Methods
Analysis set
The GT-08 trial (EudraCT No. 2004-000083-27) was a random-
ized, double-blind, placebo-controlled, 5-year Phase III trial
designed to assess the efficacy and safety of the SQ grass
sublingual immunotherapy (SLIT)-tablet to treat rhinocon-
junctivitis in subjects with seasonal grass pollen allergy14,23.
The grass pollen season was defined between the first and
last day of 3 consecutive days with pollen count larger than
or equal to 10 grains/m3. At the start of the trial, 634 sub-
jects were enrolled and randomized to active treatment or
placebo groups. Eligible subjects included healthy adults
with a clinical history of grass pollen-induced allergic rhino-
conjunctivitis suffering from moderate-to-severe symptoms
despite pharmacotherapy use. Throughout the trial, all sub-
jects had access to symptom-relieving medications including
desloratadine, olopatadine, budesonide, prednisone, and
asthma inhalers to control residual symptoms.
Subjects were asked to complete a daily record of rhino-
conjunctivitis symptoms and medication use in an electronic
diary. The six recorded symptoms included runny nose,
blocked nose, sneezing, itchy nose, itchy eyes, and watery
eyes. Subjects scored their rhinoconjunctivitis and asthma
symptoms on a scale from 0–3 (0¼ none, 1¼mild,
2¼moderate, 3¼ severe). Daily medication use was meas-
ured on a scale from 0–36 according to the type and dosage
of medication used. Subjects were also asked to complete
two quality-of-life instruments every week: the EQ5D and the
RQLQ24. EQ5D is a common PBM recommended by the
National Institute for Health and Care Excellence (NICE) for
estimation of health-state utilities. EQ5D measures quality-of-
life in five dimensions: mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression25. EQ5D scores are
only accurate for the day on which they are completed, so
only daily scores recorded on the same day as the EQ5D
scores were included in the analysis. The RQLQ is a disease-
specific questionnaire consisting of 28 questions in seven
domains, including activity limitation, sleep problems, nose
symptoms, eye symptoms, non-nose/eye symptoms, practical
problems, and emotional function. Subjects rate their health
in these dimensions on seven levels from no impairment to
severe impairment23.
The TT-04 trial (EudraCT No. 2004-000083-27) assessed the
efficacy and safety of the SQ tree SLIT-tablet in subjects with
allergic rhinitis and/or conjunctivitis caused by pollen from
the birch homologous group9,26. The birch homologous
group includes birch, hazel, alder, hornbeam, beech, and oak
pollen, which are classified based on similarities in chemical
structure and cross-reactivity9,26. Accordingly, patients with a
sensitivity to birch pollen are likely to react to other aller-
gens within the homologous group27,28. The birch pollen
season (BPS) is the primary season in the study, and the
birch, hazel, and alder seasons are considered the tree pollen
season (TPS). The TPS was defined between the first and last
day of 3 consecutive days with tree pollen count larger than
or equal to 10 grains/m3, excluding the days between the
pollen seasons where pollen counts fall below 10 grains/m3.
The BPS was defined by the same criteria, though the pollen
threshold was 30 grains/m3.
At the start of the trial, 634 subjects were randomized
and treated with the SQ tree SLIT-tablet or placebo for 1
year. Similar to the GT-08 trial, subjects provided a daily diary
of symptoms and medication use and RQLQ was registered
weekly. The same symptoms and medications were recorded
in both the GT-08 and TT-04 trials, with the exception of
prednisone, which was not one of the symptom-relieving
medications provided to patients in the TT-04 trial.
Prednisone made up only 1% of the overall medication
scores in the GT-08 trial and was assumed to have little
effect on the daily medication scores. Baseline characteristics
for both trials are presented in Table 1.
Model development
The GT-08 model was developed using a two-part modeling
approach because the EQ5D scores were strongly left
skewed, and 83% of EQ5D responses were clustered at 1,
indicating perfect health. This skewness is common with
EQ5D data, and a high percentage of subjects in perfect
health were expected in this case because subjects were
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required to be healthy aside from rhinoconjunctivitis symp-
toms19. Most standard statistical methods (e.g. Gamma and
Poisson distributions) are only appropriate for right-skewed
data. However, by transforming our data to a disutility scale,
we converted our data from left-skewed to right-skewed16.
We developed the model in terms of disutility (d), then trans-
formed the data back to the original utility scale (u) using
the following equation:
u ¼ 1 d:
In the first stage of the GT-08 model, EQ5D utilities were
modeled as a binary variable (0¼ imperfect health,
1¼ perfect health). In the second stage, EQ5D utilities were
modeled as a continuous variable conditional upon having
imperfect health. Both generalized estimating equations
(GEE) models and mixed effects models are appropriate to
analyze repeated measures in longitudinal data. We tested
several types of GEE models for the second stage of the
model, including identity and log link functions with
Gaussian, Poisson, and Gamma distributions. The variables
subject and year were tested as random effects.
Covariates were chosen for inclusion in the model based
on their availability in both the GT-08 and TT-04 trials and
their expected clinical relevance. The candidate covariates
included daily symptom score (DSS), daily medication score
(DMS), total combined symptom and medication score (TCS),
RQLQ index score, age, gender, asthma symptom score, his-
tory of asthma, and whether the measure was taken during
or outside of a pollen season. An interaction term between
DSS and DMS was also tested because subjects taking higher
doses of symptom-relieving medication are likely to experi-
ence reduced symptoms and vice versa. All candidate covari-
ates were included in a preliminary model. A more
parsimonious model was developed using backward selec-
tion and only the statistically significant variables (p< 0.05)
were retained in the final model.
Calculation of quality-adjusted life days (QALDs)
In this analysis, QALDs and utilities were analyzed over the
range of relative days with a least one EQ5D response in
each treatment arm within the pollen season in order to
accurately capture the utility difference. The range of dates
included in our analysis is longer than the duration of the
seasons recorded in TT-04 because it includes data from the
gaps between pollen seasons where pollen counts fall below
the defined thresholds, and because pollen seasons from dif-
ferent regions overlap. The BPS and TPS are defined in order
to capture all EQ5D responses, which is necessary in order to
capture the full difference in quality-of-life.
Results
The first stage of the two-part model predicted the probabil-
ity of imperfect health, and the second stage of the two-part
model predicted disutility conditional on imperfect health.
The best fit first stage model was a mixed effects logistic
model. A mixed effects model provided a better fit for the
second stage model as compared to the GEE model. The
subject was included as a random effect in both stages of
the model. Both parts of the model are summarized in
Table 2.
The model developed from the GT-08 trial data was then
applied to the TT-04 trial data to predict EQ5D utilities.
Figure 1 shows the predicted pooled mean utilities separated
Table 1. Baseline characteristicsa of GT-08 and TT-04 trials.
GT-08 TT-04
Placebo (n¼ 276) SQ grass SLIT-tablet (n¼ 277) Placebo (n¼ 296) SQ tree SLIT-tablet (n¼ 284)
Gender
Male 167 (61%) 164 (59%) 141 (48%) 134 (47%)
Female 109 (39%) 113 (41%) 155 (52%) 150 (53%)
Age
Mean (SD) 34.3 (10.1) 34.2 (9.5) 35.2 (13.4) 36.2 (13.5)
Median (IQR) 33 (27–40) 33 (27–39) 34.5 (25–45) 36 (26–46)
Symptom score
Mean (SD) 2.8 (3.4) 2.0 (2.8) 3.1 (2.3) 2.3 (1.9)
Median (IQR) 2 (0–5) 0 (0–3) 2.7 (1.2–4.7) 1.8 (0.8–3.4)
Medication score
Mean (SD) 2.1 (4.0) 1.5 (3.3) 3.5 (3.7) 2.5 (3.6)
Median (IQR) 0 (0–3) 0 (0–0) 2.4 (0.4–5.3) 1.0 (0.1–3.6)
Asthma symptom score
Mean (SD) 0.3 (0.89) 0.2 (0.8) 0.7 (0.9) 0.6 (0.8)
Median (IQR) 0 (0–0) 0 (0–0) 0.2 (0.1–1.0) 0.2 (0.0–0.8)
History of asthma
Yes (%) 33 (12%) 43 (15%) 123 (42%) 112 (39%)
No (%) 125 (45%) 145 (52%) 173 (58%) 172 (61%)
EQ5D score
Missing (%) 118 (43%) 89 (32%) — —
Mean (SD) 0.94 (0.14) 0.97 (0.10) — —
Median (IQR) 1 (0.5–1) 1 (1–1) — —
RQLQ score
Mean (SD) 0.91 (0.99) 0.69 (0.85) 1.14 (1.0) 0.9 (0.9)
Median (IQR) 1 (0, 1.1) 0.61 (1,1) 0.9 (0.3, 1.8) 0.6 (0.1, 1.3)
aCharacteristics based on full analysis set.
JOURNAL OF MEDICAL ECONOMICS 3
by treatment arm for the TT-04 trial. As in the clinical trial,
the tree pollen season was defined between the first and
last of 3 consecutive days with a pollen count above 10
grains/m3.
In the TT-04 trial, the duration of the BPS ranged from
10days in length to 42, and the duration of the TPS ranged
from 14 days in length to 50, depending on the region of
the pollen exposure.
Dates were defined relative to the first day of the BPS.
The full dataset analysis included all days over which there
was at least one EQ5D response in each treatment arm,
regardless of whether the pollen count of the respondent’s
region was above the threshold. Using this definition, the
length of the BPS season spanned 42 days, TPS spanned
100 days, and the full data set spanned 137 days. Mean utility
difference between SQ tree SLIT-tablet and placebo was
0.030 [95% CI¼ 0.015–0.046] during the BPS, 0.019 [95%
CI¼ 0.007–0.030] during the TPS, and 0.018 [95%
CI¼ 0.007–0.030] over the duration of the trial.
QALDs were calculated by multiplying the difference in
pooled mean utility by the length of the season of interest.
The SQ tree SLIT-tablet showed an incremental QALD benefit
of 1.26 (95% CI¼ 0.619–1.917) during the 42-day BPS, 1.90
(95% CI¼ 0.692–3.047) during the entire 100-day TPS, and
2.47 (95% CI¼ 0.930–4.101) over the full 137-day duration of
the trial (Table 3). Confidence intervals were computed using
bootstrap estimation, and all utility and QALD differences
were statistically significant given the exclusion of zero in
the 95% confidence intervals. All statistical analyses were
performed using Stata version 14.
Discussion
The pooled mean utilities presented in Figure 1 show a clear
difference between the treatment arms, that is most
Table 2. Summary of GT-08 model.
Stage 1 Stage 2
Variable Coef. p-value Coef. p-value
Symptom score 0.069 <0.001 0.003 0.011
Medication score 0.070 <0.001 0.002 0.089
Interaction (symptoms and medication) 0.010 <0.001 0.000 0.001
RQLQ score 1.869 <0.001 0.051 <0.001
Sex 0.623 0.009 — —
Asthma symptoms — — 0.015 <0.001
Intercept 4.587 <0.001 0.141 <0.001
Akaike information criterion (AIC) 7712 3487
Figure 1. Pooled mean daily utilities and pollen counts, SQ-SLIT trial (Stata).
Table 3. Estimated utilities and QALDs for SQ-SLIT tablet.
Date range Estimate Standard error 95% Confidence Interval
Birch Pollen season 0 to 41 Mean utility difference 0.030 0.008 0.015–0.046
QALDs 1.26 0.331 0.619–1.917
Tree Pollen season 58 to 41 Mean utility difference 0.019 0.006 0.007–0.030
QALDs 1.90 0.601 0.692–3.047
Full data set 64 to 72 Mean utility difference 0.018 0.006 0.007–0.030
QALDs 2.47 0.809 0.930–4.101
Widest date range including at least one data point for each treatment arm.
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pronounced during the BPS and appears to persist beyond
the day when the birch pollen counts drop below the season
threshold of 30 grains/m3. The difference in treatment arms
beyond the season may be related to the priming effect. The
alder and hazel seasons occur prior to the birch season, and
early exposure to these cross-reactive pollens may prime
patients to experience elevated symptoms, even after a
reduction in pollen levels29. The data points on the outer
edges of Figure 1 show a greater spread because fewer sub-
jects provided data outside of the pollen season. The
smoothed curves intersect when the pollen levels drop well
below the threshold and the impact of pollen levels on
EQ5D is negligible.
The SQ tree SLIT-tablet inhibits human IgE binding of
birch, alder, hazel, and oak allergen extracts9,27,28. Oak pollen
counts were not included in the TPS because the peak of
the oak pollen season occurs a month after the peak of the
BPS30. Although the pollen counts of the oak seasons were
not reported in this trial, the extended treatment effect vis-
ible in Figure 1 may be caused by a treatment-related reduc-
tion in oak allergy symptoms or the priming effect.
The benefit of the algorithm is that it allows mapping of
clinical results to the generic outcome of QALYs. However,
the generalizability of this algorithm is limited to allergy trials
containing the same covariates as those present in the
model. The analysis also assumes that grass pollen allergy
and tree pollen allergy have the same relationship with
EQ5D utilities and other key covariates in the mapping algo-
rithm. This assumption is supported by the fact that both
grass and tree pollen induce similar allergic rhinitis symp-
toms2,29. The trials are also similar in terms of patient popu-
lation, exclusion criteria, and baseline characteristics
(Table 1). Both trials collected symptom, medication, and
asthma scores daily, and quality-of-life data weekly, and
symptoms were rated using the same scale. This algorithm
may be applicable to other allergy trials of similar design,
patient population, and symptomology.
A notable difference between the trials is the use of pred-
nisone as a rescue medication. Prednisone was available to
subjects in the GT-08 trial, but was not available to the sub-
jects in TT-04. The impact of prednisone on symptoms and
medication use is captured in the mapping function despite
the fact that it was not used in the TT-04 trial. However,
prednisone represents only 1% of the overall medication
scores in the GT-08 trial and is unlikely to have significantly
impacted medication scores. Another difference between the
trials is the overall duration of treatment. Subjects in the GT-
08 trial were treated for 3 years and followed for 2 years after
treatment discontinuation, while subjects in the TT-04 trial
were treated for an average of 32weeks. The European
Academy of Allergy and Clinical Immunology (EAACI) guide-
lines for allergy treatment recommend at least 3 years of AIT
treatment to achieve a long-term treatment effect and
improvement in quality-of-life31. Additional treatment and
follow-up is needed to assess sustained improvement in
quality-of-life.
The algorithm developed in this analysis maps from the
disease-specific measure RQLQ to generic EQ5D. RQLQ,
which asks subjects to rate symptoms over the previous
week, is used to predict EQ5D, which is a daily measure. The
lack of concordance between the time frames of the two
measures may dilute the association. Nevertheless, our
results do show empirically that the measures are associated.
Conclusions
An effective mapping function was developed based on
grass SLIT-tablet trial data for use in a tree pollen SLIT-tablet
trial with the caveat that we are extrapolating data from
grass seasonal allergy to tree seasonal allergy. The applica-
tion of the mapping function allows the calculation of
QALDs associated with the tree SLIT-tablet treatment, which
avoids the cost of a new trial and can be used for future
cost-utility analysis. The results show a significant QALD
benefit of the SQ tree SLIT-tablet over placebo in treatment
of tree pollen-induced rhinoconjunctivitis.
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